Form 4 for REVB REVELATION BIOSCIENCES, INC.
Accepted 2026-08-18 17:00:12 ET · period of report 2026-08-17 · accession 0001193125-26-355663 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 17:00 | 2026-08-17 | REVB | Rolke James | CEO, Dir | A - Grant | $0.00 | +208.1K | 422.8K | +97% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | A | A | 208,076 | $0.00 | 422,814 | D | — | — | (F1) These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. |